Augmentation of radiation response with the vascular targeting agent ZD6126

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 5, 2006, Pages 1458-1465

  Hoang, Tien ^a   Huang, Shyhmin ^b   Armstrong, Eric ^b   Eickhoff, Jens C ^b   Harari, Paul M ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Angiogenesis; Radiation; Vascular targeting; ZD6126

Indexed keywords

CELLS; PHYSIOLOGICAL MODELS; RADIOTHERAPY; TUMORS;

ANGIOGENESIS; LUNG CANCER CELLS; VASCULAR TARGETING; ZD6126;

RADIATION EFFECTS;

MATRIGEL; N ACETYLCOLCHINOL PHOSPHATE; VASCULAR TARGETING AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; NUDE MOUSE; PRIORITY JOURNAL; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; G2 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; LAMININ; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; PROTEOGLYCANS; RANDOM ALLOCATION; S PHASE; UMBILICAL VEINS;

EID: 33645340325     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.11.017     Document Type: Article

References (34)

1. T. Hoang, R. Xu, J.H. Schiller Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data J Clin Oncol 23 2005 175 183
2. D.W. Siemann, M.C. Bibby, G.G. Dark Differentiation and definition of vascular-targeted therapies Clin Cancer Res 11 2005 416 420
3. J. Folkman, M. Klagsbrun Angiogenic factors Science 235 1987 442 447
4. P.D. Davis, G.J. Dougherty, D.C. Blakey ZD6126 A novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res 62 2002 7247 7253
5. D.C. Blakey, F.R. Westwood, M. Walker Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models Clin Cancer Res 8 2002 1974 1983
6. D.C. Blakey, S.E. Ashton, F.R. Westwood ZD6126 A novel small molecule vascular targeting agent Int J Radiat Oncol Biol Phys 54 2002 1497 1502
7. D.W. Siemann, A.M. Rojiani Enhancement of radiation therapy by the novel vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 53 2002 164 171
8. P. Wachsberger, R. Burd, A.P. Dicker Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents Exploring mechanisms of interaction Clin Cancer Res 9 2003 1957 1971
9. D.W. Siemann, A.M. Rojiani The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors Int J Radiat Oncol Biol Phys 62 2005 846 853
10. D. Raben, C. Bianco, V. Damiano Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model Mol Cancer Ther 3 2004 977 983
11. M.R. Horsman, R. Murata Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response Int J Radiat Oncol Biol Phys 57 2003 1047 1055
12. P.R. Wachsberger, R. Burd, N. Marero Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma Clin Cancer Res 11 2005 835 842
13. L. Li, A. Rojiani, D.W. Siemann Targeting the tumor vasculature with combretastatin A-4 disodium phosphate Effects on radiation therapy Int J Radiat Oncol Biol Phys 42 1998 899 903
14. L. Li, A.M. Rojiani, D.W. Siemann Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma Acta Oncol 41 2002 91 97
15. R. Murata, J. Overgaard, M.R. Horsman Combretastatin A-4 disodium phosphate A vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy Int J Radiat Oncol Biol Phys 51 2001 1018 1024
16. N. Akhtar, E.B. Dickerson, R. Auerbach The sponge/Matrigel angiogenesis assay Angiogenesis 5 2002 75 80
17. D.S. Grant, H.K. Kleinman Regulation of capillary formation by laminin and other components of the extracellular matrix Exs 79 1997 317 333
18. S.M. Huang, J. Li, E.A. Armstrong Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa) Cancer Res 62 2002 4300 4306
19. G. Micheletti, M. Poli, P. Borsotti Vascular-targeting activity of ZD6126, a novel tubulin-binding agent Cancer Res 63 2003 1534 1537
20. J.L. Evelhoch, P.M. LoRusso, Z. He Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 Clin Cancer Res 10 2004 3650 3657
21. S.P. Robinson, D.J. McIntyre, D. Checkley Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging Br J Cancer 88 2003 1592 1597
22. J. Folkman Tumor angiogenesis and tissue factor Nat Med 2 1996 167 168
23. P. Wachsberger, R. Burd, A.P. Dicker Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways Hematol Oncol Clin North Am 18 2004 1039 1057 viii
24. M. Garcia-Barros, F. Paris, C. Cordon-Cardo Tumor response to radiotherapy regulated by endothelial cell apoptosis Science 300 2003 1155 1159
25. D.W. Siemann, A.M. Rojiani Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 54 2002 1512 1517
26. T. Hoang, S. Huang, E. Armstrong Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474 Proc Am Assoc Cancer Res 45 2004 955
27. K.J. Williams, B.A. Telfer, S. Brave ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy Schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
28. C. Hess, V. Vuong, I. Hegyi Effect of VEGF receptor inhibitor PTK787/ZK222584 combined with ionizing radiation on endothelial cells and tumour growth Br J Cancer 85 2001 2010 2016
29. D. Zips, F. Hessel, M. Krause Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice Int J Radiat Oncol Biol Phys 61 2005 908 914
30. D. Zips, M. Krause, F. Hessel Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation Anticancer Res 23 2003 3869 3876
31. R.J. Griffin, B.W. Williams, R. Wild Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response Cancer Res 62 2002 1702 1706
32. S. Ning, D. Laird, J.M. Cherrington The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation Radiat Res 157 2002 45 51
33. M. Bischof, A. Abdollahi, P. Gong Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells Int J Radiat Oncol Biol Phys 60 2004 1220 1232
34. P.E. Huber, M. Bischof, J. Jenne Trimodal cancer treatment Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy Cancer Res 65 2005 3643 3655